v3.25.1

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2025	Dec. 31, 2024
Current assets
Cash	$ 2,749,959	$ 4,091,990
Acquired patents, net	876	1,779
Total assets	2,750,835	4,093,769
Current liabilities
Accounts payable & accrued interest	1,047,881	1,177,536
Deferred compensation	306,281	306,281
Unreimbursed expenses	84,362	75,916
Total current liabilities	1,438,524	1,559,733
Total liabilities	1,438,524	1,559,733
Stockholders’ equity
Common stock, $0.001 par value; 100,000,000 shares authorized; 13,192,647 and 13,152,729 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	13,193	13,153
Additional paid-in capital	70,710,858	68,674,261
Accumulated deficit	(69,411,740)	(66,153,378)
Total stockholders’ equity	1,312,311	2,534,036
Total liabilities and stockholders’ equity	$ 2,750,835	$ 4,093,769

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Greenwich LifeSciences, Inc. 10-Q